deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT05305547

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (SCORPIO-HR)

A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Interventions Placebo S-217622
Updated 27 times since 2022 Last updated: Sep 12, 2025 Started: Aug 3, 2022 Primary completion: Jan 7, 2024 Completion: May 24, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05305547, this PHASE3 trial focuses on SARS-CoV-2 Infection and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 27 times since 2022, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

27 versions recorded
  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jun 2025 — Jul 2025 [monthly]

    Completed PHASE3

  5. Feb 2025 — Jun 2025 [monthly]

    Completed PHASE3

Show 22 earlier versions
  1. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE3

  2. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  4. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  6. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE3

  7. Nov 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  8. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  9. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  10. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  11. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  12. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  13. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  14. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  15. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  16. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  17. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  18. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  19. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  20. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  21. May 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE3

  22. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Shionogi
Data source: Shionogi Inc.

For direct contact, visit the study record on ClinicalTrials.gov .